- Home
- EW vs IQV Comparison
EW vs IQV Comparison
Compare EW & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EW
- IQV
- Stock Information
- Founded
- EW 1958
- IQV 1982
- Country
- EW United States
- IQV United States
- Employees
- EW N/A
- IQV N/A
- Industry
- EW Industrial Specialties
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- EW Health Care
- IQV Health Care
- Exchange
- EW Nasdaq
- IQV Nasdaq
- Market Cap
- EW 42.5B
- IQV 35.7B
- IPO Year
- EW 2000
- IQV 2013
- Fundamental
- Price
- EW $72.86
- IQV $193.95
- Analyst Decision
- EW Buy
- IQV Strong Buy
- Analyst Count
- EW 21
- IQV 17
- Target Price
- EW $79.95
- IQV $251.00
- AVG Volume (30 Days)
- EW 4.4M
- IQV 1.4M
- Earning Date
- EW 02-11-2025
- IQV 02-06-2025
- Dividend Yield
- EW N/A
- IQV N/A
- EPS Growth
- EW 202.97
- IQV 2.74
- EPS
- EW 6.97
- IQV 7.49
- Revenue
- EW $5,439,500,000.00
- IQV $15,405,000,000.00
- Revenue This Year
- EW $10.27
- IQV $4.25
- Revenue Next Year
- EW $9.72
- IQV $6.20
- P/E Ratio
- EW $31.32
- IQV $25.51
- Revenue Growth
- EW N/A
- IQV 2.81
- 52 Week Low
- EW $58.93
- IQV $187.62
- 52 Week High
- EW $96.12
- IQV $261.73
- Technical
- Relative Strength Index (RSI)
- EW 50.53
- IQV 41.52
- Support Level
- EW $70.10
- IQV $190.76
- Resistance Level
- EW $76.73
- IQV $198.90
- Average True Range (ATR)
- EW 1.25
- IQV 5.30
- MACD
- EW 0.11
- IQV -1.14
- Stochastic Oscillator
- EW 44.04
- IQV 8.38
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.